ReviewMolecular imaging and biology2026
Theranostic and Radionuclide-based Treatment Approaches for Radioiodine-refractory Thyroid Cancer: From Biology to Clinical Application.
Review in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Signaling pathways and targeted therapy in high‑risk refractory thyroid cancer: From bench to bedside (Review).International journal of oncology · 2026Review
- Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
When differentiated thyroid cancer stops taking up radioiodine, treatment becomes significantly more challenging, and the disease often behaves more aggressively. Systemic therapies such as multikinase inhibitors and mutation-specific drugs have expanded available options, but many patients experience side effects, and responses can vary widely. At the same time, advances in molecular imaging and targeted radionuclide therapy are changing how this condition is managed. Short-term MAPK inhibition can restore iodine uptake in some patients, creating an opportunity to give radioiodine again. For patients with spreading or fast-growing disease, a growing range of theranostic agents, including
Indexed as
Identifiers
41708943What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.